PE20211455A1 - Moduladores del receptor nmda espiro-lactama y usos de los mismos - Google Patents
Moduladores del receptor nmda espiro-lactama y usos de los mismosInfo
- Publication number
- PE20211455A1 PE20211455A1 PE2020001149A PE2020001149A PE20211455A1 PE 20211455 A1 PE20211455 A1 PE 20211455A1 PE 2020001149 A PE2020001149 A PE 2020001149A PE 2020001149 A PE2020001149 A PE 2020001149A PE 20211455 A1 PE20211455 A1 PE 20211455A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- group
- spiro
- independently selected
- lactama
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Referido a un compuesto seleccionado entre A, B, C, D, E, G, H, I, en donde R1 esta independientemente seleccionado del grupo que consiste de H, -alquilo C1-C6, -C(O)-alquilo C1-C6, entre otros; R5 se selecciona independientemente para cada aparicion del grupo que consiste de H, -alquilo C1-C6, y halogeno; R6 se selecciona independientemente para cada aparicion del grupo que consiste de H, -alquilo C1-C6, y halogeno; R7 se selecciona independientemente para cada aparicion del grupo que consiste de H, -alquilo C1-C6, fenilo, entre otros; R3 se selecciona del grupo que consiste de H, -alquilo C1-C6, fenilo, -C(O)-R31, entre otros; una sal farmaceuticamente aceptable y/o estereoisomero del mismo. Estos compuestos son moduladores del receptor de N-metil-d-aspartato (NMDA) espiro-lactama y su uso en el tratamiento de la depresion, enfermedad de Alzheimer, trastorno de deficit de atencion, migrana, entre otros.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862624218P | 2018-01-31 | 2018-01-31 | |
| US201862718107P | 2018-08-13 | 2018-08-13 | |
| PCT/US2019/016098 WO2019152678A1 (en) | 2018-01-31 | 2019-01-31 | Spiro-lactam nmda receptor modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211455A1 true PE20211455A1 (es) | 2021-08-05 |
Family
ID=65494516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001149A PE20211455A1 (es) | 2018-01-31 | 2019-01-31 | Moduladores del receptor nmda espiro-lactama y usos de los mismos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210047324A1 (es) |
| EP (1) | EP3746442A1 (es) |
| JP (2) | JP2021512109A (es) |
| KR (1) | KR20200115610A (es) |
| CN (1) | CN112218866A (es) |
| AU (1) | AU2019215049A1 (es) |
| BR (1) | BR112020015666A2 (es) |
| CA (1) | CA3089559A1 (es) |
| CL (1) | CL2020001990A1 (es) |
| IL (1) | IL276330A (es) |
| MX (1) | MX2020008106A (es) |
| PE (1) | PE20211455A1 (es) |
| PH (1) | PH12020551140A1 (es) |
| SG (1) | SG11202007251XA (es) |
| WO (1) | WO2019152678A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102465757B1 (ko) | 2016-08-01 | 2022-11-09 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
| ES2974090T3 (es) | 2016-08-01 | 2024-06-25 | Tenacia Biotechnology Hong Kong Co Ltd | Moduladores de NMDA de espirolactama y métodos de uso de los mismos |
| EP3490992B1 (en) | 2016-08-01 | 2023-03-22 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| CN109906218B (zh) | 2016-08-01 | 2023-01-17 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
| SG11202007256PA (en) | 2018-01-31 | 2020-08-28 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof |
| CA3092470A1 (en) | 2018-02-27 | 2019-09-06 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
| CA3100731A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| TW202402759A (zh) | 2018-07-05 | 2024-01-16 | 美商英塞特公司 | 作為a2a/a2b抑制劑之稠合吡嗪衍生物 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶 |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
| WO2024054919A1 (en) * | 2022-09-08 | 2024-03-14 | Tenacia Biotechnology (Hong Kong) Co., Limited | Spiro-lactam nmda receptor modulators and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011003015A (es) * | 2008-09-18 | 2011-11-18 | Univ Northwestern | Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos. |
| TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| CN105037492A (zh) * | 2010-02-11 | 2015-11-11 | 西北大学 | 二级结构稳定化的nmda受体调节剂及其用途 |
| DK2951183T3 (da) * | 2013-01-29 | 2019-06-03 | Aptinyx Inc | Spiro-lactam-nmda-receptormodulatorer og anvendelser heraf |
| WO2014120800A1 (en) * | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| EP2951184A1 (en) * | 2013-01-29 | 2015-12-09 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| AU2014212485C1 (en) * | 2013-01-29 | 2018-10-25 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| AU2014212490A1 (en) * | 2013-01-29 | 2015-07-30 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| WO2017201285A1 (en) * | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| KR102128675B1 (ko) * | 2016-05-19 | 2020-06-30 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
| JP2022092387A (ja) * | 2020-12-10 | 2022-06-22 | キヤノン株式会社 | 画像形成装置 |
-
2019
- 2019-01-31 PE PE2020001149A patent/PE20211455A1/es unknown
- 2019-01-31 KR KR1020207024903A patent/KR20200115610A/ko unknown
- 2019-01-31 SG SG11202007251XA patent/SG11202007251XA/en unknown
- 2019-01-31 JP JP2020541807A patent/JP2021512109A/ja active Pending
- 2019-01-31 CA CA3089559A patent/CA3089559A1/en active Pending
- 2019-01-31 US US16/966,176 patent/US20210047324A1/en not_active Abandoned
- 2019-01-31 WO PCT/US2019/016098 patent/WO2019152678A1/en unknown
- 2019-01-31 BR BR112020015666-3A patent/BR112020015666A2/pt not_active Application Discontinuation
- 2019-01-31 MX MX2020008106A patent/MX2020008106A/es unknown
- 2019-01-31 EP EP19706076.7A patent/EP3746442A1/en active Pending
- 2019-01-31 CN CN201980018351.6A patent/CN112218866A/zh active Pending
- 2019-01-31 AU AU2019215049A patent/AU2019215049A1/en active Pending
-
2020
- 2020-07-27 IL IL276330A patent/IL276330A/en unknown
- 2020-07-28 PH PH12020551140A patent/PH12020551140A1/en unknown
- 2020-07-30 CL CL2020001990A patent/CL2020001990A1/es unknown
-
2023
- 2023-11-10 JP JP2023192455A patent/JP2024019396A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA3089559A1 (en) | 2019-08-08 |
| SG11202007251XA (en) | 2020-08-28 |
| CN112218866A (zh) | 2021-01-12 |
| US20210047324A1 (en) | 2021-02-18 |
| IL276330A (en) | 2020-09-30 |
| AU2019215049A1 (en) | 2020-09-17 |
| JP2021512109A (ja) | 2021-05-13 |
| KR20200115610A (ko) | 2020-10-07 |
| MX2020008106A (es) | 2020-09-25 |
| CL2020001990A1 (es) | 2021-03-26 |
| WO2019152678A1 (en) | 2019-08-08 |
| PH12020551140A1 (en) | 2021-05-31 |
| JP2024019396A (ja) | 2024-02-09 |
| EP3746442A1 (en) | 2020-12-09 |
| BR112020015666A2 (pt) | 2021-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211455A1 (es) | Moduladores del receptor nmda espiro-lactama y usos de los mismos | |
| PE20190503A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| CO2019007129A2 (es) | Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador | |
| CO2017004481A2 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
| UY37310A (es) | Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo | |
| CO2020001220A2 (es) | Compuestos, composiciones y métodos | |
| AR109561A1 (es) | Compuestos modulares de receptores tipo toll | |
| PE20180462A1 (es) | Moduladores cot y metodos de uso de los mismos | |
| PE20190501A1 (es) | Moduladores nmda espiro-lactam y metodos de uso de los mismos | |
| ECSP20053845A (es) | Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosis quística y procesos para elaborarlos | |
| AR114803A1 (es) | Compuestos de 4-aminoisoindolin-1,3-diona sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos | |
| CO2019003974A2 (es) | Compuestos y métodos para la modulación de ido y tdo e indicaciones de estos. | |
| PE20190504A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| CL2020001546A1 (es) | Compuestos de 4-azaindol. | |
| PE20212302A1 (es) | Inhibidores de apol1 y sus metodos de uso | |
| CR20190124A (es) | Inhibidores de ssao de aminopirimidina | |
| PE20191495A1 (es) | Piridonamidas como moduladores de canales de sodio | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR108202A1 (es) | Reducción de la carga tumoral minimal mediante la administración de antagonistas de ccr1 en combinación con inhibidores de pd-1 o inhibidores pd-l1 | |
| CO2020014217A2 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| PE20221457A1 (es) | Degradadores de moleculas pequenas de helios y procedimientos de uso | |
| MX2020003666A (es) | Compuestos y composiciones para el tratamiento de trastornos hematologicos. | |
| AR102361A1 (es) | Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| ECSP12012326A (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
| PE20170324A1 (es) | Anticuerpos dirigidos contra cd127 |